Roth Capital Notes Discontinued CBD Products Impacting FitLife Brands, Inc. (FTLF)
Roth Capital has lowered its price target for FitLife Brands, Inc. (FTLF) to $17 from $25, citing weaker-than-expected fourth-quarter results driven by declining demand, higher protein costs, and the discontinuation of CBD products. The company reported $25.9 million in revenue for the quarter, with most brand groups performing well except for MRC, which saw a 15% revenue decline.
Topics: analyst report earnings product discontinuation revenue stock performance